GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report
The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...
Managed Healthcare Executive2d
Trelegy and Breo Offer Incremental Improvement Over Generics
The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
The Pharma Letter1d
ICER seeks to judge value of Trelegy and Breo Ellipta in COPD
The Institute for Clinical and Economic Review (ICER) has published a special report on chronic obstructive pulmonary disease (COPD) therapies as part of the Centers for Medicare & Medicaid Services ...
pharmaphorum3d
GSK’s Relvar Ellipta comes out on top in real world study
Relvar Ellipta is a once-daily dual combination treatment comprising fluticasone furoate, an inhaled corticosteroid and vilanterol, a long-acting beta2-agonist, in a single inhaler, the Ellipta.
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...
rarediseaseadvisor6d
Q&A With an AATD Carrier
Read about AATD symptoms I have been taking Breo Ellipta once a day for almost 5 years now, and most, if not all, of my symptoms have been kept at bay, thankfully. Unfortunately, I’m somewhat ...
BMJ2d
Real-world evidence is a vital tool for informing treatment strategies in chronic obstructive pulmonary disease
The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...